Clinical Trial News and Research

RSS

Emergent BioSolutions awarded $3.8 million to develop anthrax immune globulin therapeutic

Emergent BioSolutions has announced that it has been awarded two grants from the National Institute of Allergy and Infectious Diseases (NIAID) totaling $3.8 million to support the development of the company's anthrax immune globulin (AIG) therapeutic product.

1 Sep 2006

New technique to statistically analyze results of clinical trials

Statisticians at St. Jude Children's Research Hospital have developed a new technique that allows researchers to statistically analyze results of clinical trials.

1 Sep 2006

VIOXX reduces risk of colorectal polyps

A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.

30 Aug 2006

FDA advisory panel recommends approval of experimental preterm labor prevention drug

An FDA advisory committee on Tuesday voted 13-8 that clinical trial data regarding Adeza's experimental preterm labor prevention drug Gestiva was adequate to approve the drug, Dow Jones reports (Corbett Dooren, Dow Jones, 8/29).

30 Aug 2006

FDA questions effectiveness of Gestiva at preventing preterm labor

FDA in a review of Adeza's experimental preterm labor prevention drug Gestiva said the drug seems to reduce deliveries before 37 weeks' gestation but not births before 32 or 35 weeks' gestation, according to documents posted Monday on the agency's Web site.

30 Aug 2006

Medicare policy offering coverage for certain treatments to clinical trial participants examined

"Medicare's Requirement for Research Participation as a Condition of Coverage: Is it Ethical?" Journal of the American Medical Association.

24 Aug 2006

GenoMed's third horse with presumed West Nile Virus recovers after treatment

GenoMed has announced that the third horse in its expanded trial for West Nile virus encephalitis recovered markedly within 24 hours after starting GenoMed's treatment.

21 Aug 2006

FDA approves Plavix for STEMI heart attacks

The Food and Drug Administration (FDA) today approved the use of Plavix (clopidogrel bisulfate) for patients who have had a type of heart attack called acute ST-segment elevation myocardial infarction (STEMI), who are not going to have coronary artery repair (angioplasty).

17 Aug 2006

First treatment for Hunter disease

An article reporting results from a pivotal clinical trial that helped gain U.S. Food and Drug Administration approval for the first treatment for Hunter disease has been published online by the journal Genetics in Medicine.

16 Aug 2006

AIDS vaccine still long way off

Researchers are optimistic about a potential HIV/AIDS vaccine, even though none of the vaccines in development is likely to completely protect people from HIV transmission, participants at the XVI International AIDS Conference in Toronto said at a news conference Tuesday, Reuters reports.

16 Aug 2006

Male circumcision, microbicides and other tools set to change HIV prevention landscape

In a new report released this week, fifty top AIDS experts warn that a range of promising new HIV prevention approaches are nearing completion of clinical trials, but the world is unprepared to ensure widespread access for those in need.

15 Aug 2006

Argatroban may promote opening of arteries following stroke

A medication known as argatroban, when combined with another drug already used in the treatment of stroke patients, may help restore the flow of blood through blocked arteries.

14 Aug 2006

Neuren presents phase 2 clinical trial strategy for NNZ-2566

Neuren Pharmaceuticals has announced that Mr Larry Glass, Executive Vice President and head of Neuren’s US operations, has been invited by the US Army to present Neuren’s clinical trial strategy for NNZ-2566 at the Advanced Technology Applications for Combat Casualty Care (ATACCC) conference.

14 Aug 2006